On August 18, patients suffered adverse drug reactions after two antibiotics were administered intravenously by doctors at a civic-run hospital, the PIL filed by activist Ketan Tirodkar submitted.
Of the 45 patients, 28 patients suffered severe reactions. Among them one Saira Shaikh died within 24 hours of the reaction and Food and Drug Administration (FDA) officials seized Saira's records from a hospital, the PIL, which is expected to come up for hearing tomorrow, said.
FDA officials visited the hospital and seized seven samples, the PIL alleged.
The PIL said that the Municipal Corporation of Greater Mumbai (MCGM) has formed a panel to investigate the reason behind the 28 patients being taken ill.
The inquiry panel would probe whether the drugs were stored improperly or in unsuitable storage condition, or whether syringes used were contaminated. The probe would also look into the quality of drugs and injection water as well as the method of administration of injections.
The PIL prayed that a CID probe be ordered and a case of negligence registered against FDA officials, municipal hospitals and pharmaceutical companies.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
